52
Views
0
CrossRef citations to date
0
Altmetric
Research Articles

43-O-(β-D-glucoside)-rapamycin, a microbial conversion product by Bacillus subtilis CGMCC7764

, , , , , & show all
Pages 374-379 | Received 13 Dec 2021, Accepted 28 Jul 2022, Published online: 25 Aug 2022
 

Abstract

Rapamycin is a macrolide antibiotic with antifungal, immunosuppressive, antitumor, and lifespan-extension activities etc. In order to increase its structural diversity, microbial transformation of rapamycin was conducted. More than 3 converted compounds were shown in the microbial conversion culture of rapamycin by Bacillus subtilis CGMCC7764. By extensive NMR and MS spectroscopic analyses, the major compound was identified as 43-O-(β-D-glucoside)-rapamycin. This compound has an inhibitory effect on tumour growth, and its activity is similar to rapamycin.

Acknowledgments

Financial support from Major National Science and Technology Projects [2020L3016] are gratefully acknowledged.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Additional information

Funding

This work was supported by the Special Foundation for State major Basic Research Program of China (2020L3016).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.